Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Janku

Showing results (171-180 of 277) with videos related to

Pageof 28
Sort By:
JAMA Oncology|December 14, 2018
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical TrialDejan Juric, Filip Janku, Jordi Rodón, et al.
JCO Precision Oncology|September 14, 2020
Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNANora S Sánchez, Michael P Kahle, Ann Marie Bailey, et al.
Cancer|March 7, 2023
A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumorsFilip Janku, Milind M Javle, Shiraj Sen, et al.
Oncotargets and Therapy|May 17, 2021
A Phase I Trial of the MET/<i>ALK/ROS1</i> Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid MalignanciesSarina A Piha-Paul, Ecaterina E Dumbrava, Binoj C Nair, et al.
The Oncologist|August 16, 2018
Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation BurdenWinnie S Liang, Jo-Anne Vergilio, Bodour Salhia, et al.
Oncotarget|October 15, 2014
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trialsRabih Said, Yang Ye, Gerald Steven Falchook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2020
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced ChondrosarcomaWilliam D Tap, Victor M Villalobos, Gregory M Cote, et al.
The Oncologist|September 20, 2022
Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck CancerFaye M Johnson, Filip Janku, Mohamed A Gouda, et al.
Cell Reports|January 21, 2014
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitorsFilip Janku, David S Hong, Siqing Fu, et al.
Plos One|December 24, 2014
Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implicationsChaitanya R Churi, Rachna Shroff, Ying Wang, et al.
Pageof 28

Showing results (171-180 of 277) with videos related to

Sort By:
Pageof 28
JAMA Oncology|December 14, 2018
Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical TrialDejan Juric, Filip Janku, Jordi Rodón, et al.
JCO Precision Oncology|September 14, 2020
Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNANora S Sánchez, Michael P Kahle, Ann Marie Bailey, et al.
Cancer|March 7, 2023
A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumorsFilip Janku, Milind M Javle, Shiraj Sen, et al.
Oncotargets and Therapy|May 17, 2021
A Phase I Trial of the MET/<i>ALK/ROS1</i> Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid MalignanciesSarina A Piha-Paul, Ecaterina E Dumbrava, Binoj C Nair, et al.
The Oncologist|August 16, 2018
Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation BurdenWinnie S Liang, Jo-Anne Vergilio, Bodour Salhia, et al.
Oncotarget|October 15, 2014
Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trialsRabih Said, Yang Ye, Gerald Steven Falchook, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2020
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced ChondrosarcomaWilliam D Tap, Victor M Villalobos, Gregory M Cote, et al.
The Oncologist|September 20, 2022
Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck CancerFaye M Johnson, Filip Janku, Mohamed A Gouda, et al.
Cell Reports|January 21, 2014
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitorsFilip Janku, David S Hong, Siqing Fu, et al.
Plos One|December 24, 2014
Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implicationsChaitanya R Churi, Rachna Shroff, Ying Wang, et al.
Pageof 28